PMID- 15266063
OWN - NLM
STAT- MEDLINE
DCOM- 20041221
LR  - 20131121
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 43
IP  - 11
DP  - 2004 Nov
TI  - Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: 
      a possible alternative.
PG  - 1383-5
AB  - OBJECTIVE: To determine the efficacy of tacrolimus ointment 0.1% on resistant 
      cutaneous lesions in patients with lupus erythematosus. METHODS: Twelve patients 
      with skin manifestations were studied. Six had discoid lupus (DL), four subacute 
      cutaneous lupus erythematosus (SCLE) and two systemic lupus erythematosus (SLE). 
      All patients had extensive skin lesions refractory to previous treatment. 
      Patients received topical tacrolimus 0.1% for a minimum of 6 weeks and response 
      was evaluated by physicians' and patients' assessment and documented with 
      photographs at baseline and at the end of the treatment. RESULTS: Eleven of 12 
      patients completed the therapy. One patient with DL discontinued because of 
      side--effects-peeling and a burning sensation. Six patients were clearly 
      improved, one patient had a minor remission of his face lesion while in four the 
      rashes remained the same. Two patients with SCLE had significant regression of 
      their lesions while the other two had no improvement. In DL, two had certain 
      improvement, one minor improvement and two were without response. The patients 
      with SLE had significant amelioration of their extensive photosensitive rash. 
      CONCLUSION: Tacrolimus ointment 0.1% may be an effective alternative in patients 
      with severe resistant cutaneous manifestations in lupus erythematosus.
FAU - Lampropoulos, C E
AU  - Lampropoulos CE
AD  - Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, 
      UK.
FAU - Sangle, S
AU  - Sangle S
FAU - Harrison, P
AU  - Harrison P
FAU - Hughes, G R V
AU  - Hughes GR
FAU - D'Cruz, D P
AU  - D'Cruz DP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20040720
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Ointments)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Lupus Erythematosus, Cutaneous/*drug therapy/pathology
MH  - Lupus Erythematosus, Discoid/drug therapy/pathology
MH  - Lupus Erythematosus, Systemic/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Ointments
MH  - Tacrolimus/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2004/07/22 05:00
MHDA- 2004/12/22 09:00
CRDT- 2004/07/22 05:00
PHST- 2004/07/22 05:00 [pubmed]
PHST- 2004/12/22 09:00 [medline]
PHST- 2004/07/22 05:00 [entrez]
AID - keh325 [pii]
AID - 10.1093/rheumatology/keh325 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2004 Nov;43(11):1383-5. doi: 10.1093/rheumatology/keh325. 
      Epub 2004 Jul 20.